Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 4/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | AGXT | P21549 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14883546 | 1.00 | CA12 (0.50) | CA12CA1CA9MAPTRAB9A | |
| SCHEMBL2308601 | 0.92 | LMNA (0.45) | CA12CA1CA9MAPTRAB9A | |
| SCHEMBL11683637 | 0.86 | CA1 (0.50) | CA12CA1CA9MAPTRAB9A | |
| SCHEMBL1982944 | 0.83 | ALDH1A1 (0.58) | MAPTRAB9AALDH1A1HPGDLMNA | |
| SCHEMBL9908262 | 0.83 | ALDH1A1 (0.58) | MAPTRAB9AALDH1A1HPGDLMNA | |
| SCHEMBL10458381 | 0.83 | CA12 (0.59) | CA12CA1CA9MAPTRAB9A | |
| SCHEMBL7273053 | 0.83 | ALDH1A1 (0.54) | CA12CA1CA9MAPTALDH1A1 | |
| SCHEMBL29935640 | 0.82 | APP (0.40) | CA12CA1CA9MAPTRAB9A | |
| SCHEMBL15650212 | 0.81 | FDPS (0.50) | MAPTRAB9AALDH1A1HPGDLMNA | |
| SCHEMBL29935870 | 0.81 | MAOA (0.58) | CA12CA1CA9RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130101509-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130101509-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130101509-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2013048832-A1 | 18 F - LABELLED 6 - ( 2 - FLUOROETHOXY) - 2 - NAPHTHALDEHYDE FOR DETECTING CANCER STEM CELLS | GE HEALTHCARE LIMITED (GB) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013048832-A1 | 18 F - LABELLED 6 - ( 2 - FLUOROETHOXY) - 2 - NAPHTHALDEHYDE FOR DETECTING CANCER STEM CELLS | GE HEALTHCARE LIMITED (GB) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013048832-A1 | 18 F - LABELLED 6 - ( 2 - FLUOROETHOXY) - 2 - NAPHTHALDEHYDE FOR DETECTING CANCER STEM CELLS | GE HEALTHCARE LIMITED (GB) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049174-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-A]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130101509-A1 | IMAGING AND RADIOTHERAPY METHODS | ALDH2, ALDH3A1, ALDH1A1 | CA12 321/4885CA1 472/4885CA9 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.